Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Genitourinary 2Thoracic 1Other hematologic neoplasm 1Breast 1

Conditions

Radiation Injuries 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hodgkin Disease 1

Interventions

Cyclophosphamide 139Vincristine 105Rituximab 100Doxorubicin 87Etoposide 79Prednisone 69Cytarabine 67Filgrastim 63Specimen Handling 62Methotrexate 60Biopsy 60Magnetic Resonance Spectroscopy 51fludarabine phosphate 50Dexamethasone 47Radiotherapy 43Peripheral Blood Stem Cell Transplantation 35Leucovorin 35Bortezomib 32Prednisolone 28Mercaptopurine 27merphos 24Ifosfamide 24Asparaginase 24Daunorubicin 23Lenalidomide 22ibrutinib 21fludarabine 21Calcium Dobesilate 21pegaspargase 19Alemtuzumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Pentetic Acid × Lymphoid × Clear all
NCT00001575 2015-12-07

Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
87 enrolled 11 charts
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT00019227 2013-06-20

Monoclonal Antibody Therapy in Treating Patients With Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
LymphoidOther hematologic neoplasm

Lymphoma, Radiation Injuries, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡